0R15 8884.0068 1.4156% 0R1E 9171.0 0.4381% 0M69 None None% 0R2V 255.53 6.2495% 0QYR 1619.0 1.9521% 0QYP 439.6 -0.2043% 0RUK None None% 0RYA 1532.0 -4.0701% 0RIH 190.8 0.0% 0RIH 193.5 1.4151% 0R1O 226.72 9954.102% 0R1O None None% 0QFP None None% 0M2Z 255.4879 -0.0829% 0VSO 33.09 -7.0636% 0R1I None None% 0QZI 599.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 227.3 2.2952%
Last update at 2024-12-19T18:48:00Z
Reasons to Retain Alcon Stock in Your Portfolio for Now
Tue 24 Sep 24, 12:42 PMInnovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
Fri 20 Sep 24, 12:26 PMAlcon Inc. (ALC): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
Tue 27 Aug 24, 10:42 PMAlcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
Wed 21 Aug 24, 12:11 PMAlcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Tue 20 Aug 24, 10:00 PMAlcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
Tue 20 Aug 24, 08:30 PMAlcon's (ALC) Market Share Gains, New Launches Aid Growth
Tue 20 Aug 24, 03:48 PMCountdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
Thu 15 Aug 24, 01:15 PMIs Alcon (ALC) Outperforming Other Medical Stocks This Year?
Mon 05 Aug 24, 01:40 PMHere's Why Alcon (ALC) is a Strong Momentum Stock
Wed 17 Jul 24, 01:50 PM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | 832.00M | 463.00M | 418.00M | -635.00000M | -332.00000M |
| Minority interest | - | - | - | - | - |
| Net income | 974.00M | 335.00M | 376.00M | -531.00000M | -656.00000M |
| Selling general administrative | 3209.00M | 3068.00M | 3057.00M | 2694.00M | 2847.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 5247.00M | 4748.00M | 4652.00M | 2940.00M | 3662.00M |
| Reconciled depreciation | 1221.00M | 1123.00M | 1219.00M | 1626.00M | 1425.00M |
| Ebit | 1021.00M | 616.59M | 539.14M | -611.36711M | -199.00000M |
| Ebitda | 2242.00M | 1776.43M | 1760.74M | 1112.00M | 1226.00M |
| Depreciation and amortization | 1221.00M | 1159.84M | 1221.59M | 1723.37M | 1425.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1039.00M | 672.00M | 580.00M | -482.00000M | -187.00000M |
| Other operating expenses | 8416.00M | 8045.00M | 7711.00M | 7315.00M | 7695.00M |
| Interest expense | 189.00M | 134.00M | 120.00M | 124.00M | 113.00M |
| Tax provision | -142.00000M | 128.00M | 42.00M | -104.00000M | 324.00M |
| Interest income | 45.00M | 16.00M | 146.00M | 6.00M | 8.00M |
| Net interest income | -155.00000M | -146.00000M | -162.00000M | -131.00000M | -125.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -142.00000M | 128.00M | 42.00M | -104.00000M | 324.00M |
| Total revenue | 9455.00M | 8717.00M | 8291.00M | 6833.00M | 7508.00M |
| Total operating expenses | 4208.00M | 4076.00M | 4072.00M | 3422.00M | 3849.00M |
| Cost of revenue | 4208.00M | 3969.00M | 3639.00M | 3893.00M | 3846.00M |
| Total other income expense net | -207.00000M | -209.00000M | -162.00000M | -153.00000M | -20.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 974.00M | 335.00M | 376.00M | -531.00000M | -656.00000M |
| Net income applicable to common shares | - | 335.00M | 376.00M | -531.00000M | -656.00000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 29614.00M | 29209.00M | 27999.00M | 27600.00M | 27655.00M |
| Intangible assets | 9060.00M | 9689.00M | 8765.00M | 9097.00M | 10231.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 241.96M | 418.00M | 95.00M | 404.00M | 90.00M |
| Total liab | 8990.00M | 9532.00M | 8743.00M | 8778.00M | 8352.00M |
| Total stockholder equity | 20617.02M | 19677.00M | 19256.00M | 18822.00M | 19303.00M |
| Deferred long term liab | - | - | 557.00M | 727.00M | 725.00M |
| Other current liab | 1338.20M | 1664.00M | 1287.00M | 1040.00M | 1064.00M |
| Common stock | 19.99M | 20.00M | 20.00M | 20.00M | 20.00M |
| Capital stock | 20.00M | 20.00M | 20.00M | 20.00M | 20.00M |
| Retained earnings | - | - | 19356.00M | 18899.00M | 19355.00M |
| Other liab | - | 1850.00M | 1966.00M | 2256.00M | 2554.00M |
| Good will | 8926.00M | 8970.00M | 8905.00M | 8905.00M | 8905.00M |
| Other assets | -10.02816M | 833.00M | 1365.00M | 1515.00M | 1512.00M |
| Cash | 1094.00M | 980.00M | 1575.00M | 1557.00M | 822.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2479.16M | 2782.00M | 2472.00M | 2258.00M | 2300.00M |
| Current deferred revenue | -0.83980M | 89.00M | 108.00M | 110.00M | 97.00M |
| Net debt | 4041.00M | 4088.00M | 2904.00M | 2939.00M | 2982.00M |
| Short term debt | 216.00M | 168.00M | 174.00M | 232.00M | 306.00M |
| Short long term debt | 135.00M | 97.00M | 107.00M | 162.00M | 245.00M |
| Short long term debt total | 5135.00M | 5068.00M | 4479.00M | 4496.00M | 3804.00M |
| Other stockholder equity | - | 19657.00M | 19236.00M | 18802.00M | -19355.00000M |
| Property plant equipment | - | 4416.00M | 4083.00M | 3783.00M | 3437.00M |
| Total current assets | 5647.00M | 5193.00M | 5386.00M | 4987.00M | 4236.00M |
| Long term investments | 319.00M | 108.00M | 52.00M | 40.00M | 59.00M |
| Net tangible assets | - | 1018.00M | 2143.00M | 1547.00M | 892.00M |
| Short term investments | 7.00M | -179.00000M | 3.00M | 12.00M | 33.00M |
| Net receivables | 1981.33M | 1686.00M | 1814.00M | 1382.00M | 1786.00M |
| Long term debt | 4594.00M | 4541.00M | 3966.00M | 3949.00M | 3218.00M |
| Inventory | 2322.00M | 2109.00M | 1899.00M | 1644.00M | 1505.00M |
| Accounts payable | 811.00M | 861.00M | 903.00M | 876.00M | 833.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 20597.02M | 19657.00M | 19236.00M | 18802.00M | 19283.00M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 20.00M | 20.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 496.15M | 243.00M | 399.00M | 211.00M | 433.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 23967.00M | 24016.00M | 22613.00M | 22613.00M | 23419.00M |
| Capital lease obligations | 406.00M | 430.00M | 406.00M | 385.00M | 341.00M |
| Long term debt total | - | - | 4305.00M | 4264.00M | 3498.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1865.00000M | -18.00000M | -572.00000M | -1011.00000M | -1001.00000M |
| Change to liabilities | -48.00000M | 60.00M | -21.00000M | 84.00M | 44.00M |
| Total cashflows from investing activities | -1865.00000M | -1198.00000M | -572.00000M | -1011.00000M | -1001.00000M |
| Net borrowings | 208.00M | -63.00000M | 536.00M | 3293.00M | 15.00M |
| Total cash from financing activities | -8.00000M | -123.00000M | 466.00M | 659.00M | -78.00000M |
| Change to operating activities | -192.00000M | 88.00M | -23.00000M | 8.00M | 66.00M |
| Net income | 335.00M | 376.00M | -531.00000M | -656.00000M | -227.00000M |
| Change in cash | -595.00000M | 18.00M | 735.00M | 595.00M | 55.00M |
| Begin period cash flow | 1575.00M | 1557.00M | 822.00M | 227.00M | 172.00M |
| End period cash flow | 980.00M | 1575.00M | 1557.00M | 822.00M | 227.00M |
| Total cash from operating activities | 1217.00M | 1345.00M | 823.00M | 920.00M | 1140.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1123.00M | 1219.00M | 1626.00M | 1425.00M | 1638.00M |
| Other cashflows from investing activities | - | -18.00000M | -5.00000M | -1.00000M | -1.00000M |
| Dividends paid | -100.00000M | -54.00000M | 54.00M | 54.00M | 54.00M |
| Change to inventory | -217.00000M | -326.00000M | -159.00000M | -108.00000M | -150.00000M |
| Change to account receivables | -164.00000M | -198.00000M | 43.00M | -115.00000M | 53.00M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 2428.00M | 3.00M | 535.00M | 2720.00M | -78.00000M |
| Change to netincome | 380.00M | 128.00M | -101.00000M | 290.00M | -284.00000M |
| Capital expenditures | 745.00M | 1180.00M | 567.00M | 676.00M | 712.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -527.00000M | -314.00000M | -45.00000M | -48.00000M | 80.00M |
| Stock based compensation | 140.00M | 138.00M | 105.00M | 83.00M | -234.00000M |
| Other non cash items | 18.00M | -116.00000M | -228.00000M | -208.00000M | -44.00000M |
| Free cash flow | 472.00M | 165.00M | 256.00M | 244.00M | 428.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALC Alcon AG |
0.01 0.01% | 84.75 | 36.95 | 25.13 | 4.40 | 2.32 | 4.80 | 36.97 |
| ISRG Intuitive Surgical Inc |
3.11 0.59% | 529.58 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.64 0.53% | 119.68 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
-3.5 1.44% | 240.00 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
1.06 0.47% | 225.15 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Chemin de Blandonnet 8, Geneva, Switzerland, 1214
| Name | Title | Year Born |
|---|---|---|
| Mr. F. Michael Ball | Exec. Chairman | 1955 |
| Mr. David J. Endicott | CEO & Director | 1965 |
| Mr. Arthur B. Cummings M.D. | Exec. Director | 1962 |
| Mr. Timothy C. Stonesifer | Chief Financial Officer | 1967 |
| Margaret Buckley | Chief Accounting Officer | NA |
| Dr. Franck Leveiller | Sr. VP, Head of Global R&D and Chief Scientific Officer | NA |
| Ms. Sue-Jean Lin | Sr. VP & Chief Information and Transformation Officer | 1969 |
| Mr. Royce R. Bedward | Sr. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Mr. Laurent Attias | Head of Corp. Devel., Strategy, BD&L and M&A | 1968 |
| Ms. Kimberly Martin | Sr. VP & Chief HR Officer | 1975 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...